Eden Research plc (EDEN) Fair Value & Analysis
Basic Materials · GB · Market cap 27.7M GBX
Fair value as of: Jun 26, 2026
From 1 valuation models · updated 3 days ago
Fair value updated Jun 26, 2026 — revised from £0.0400 to £0.0240 (−40.0%) since Jun 24, 2026. Share price −13.0% over the past month.
Price vs Fair Value (12 months)
12‑month range £0.0210 – £0.0480 · the £0.0300 price screens above the £0.0240 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Eden Research plc (EDEN) currently trades at £0.0300, while our model-based Fair Value estimate is £0.0240 — implying the stock looks roughly 20.0% overvalued today. We read business quality at 92/100 (high quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Eden Research plc generated revenue of £3.6M at a net margin of -65.0%. Revenue declined 36.4% year over year. It earns a return on equity of -20.1%. The balance sheet holds a net cash position of £3.5M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Eden Research plc, together with its subsidiaries, engages in the development and sale of biopesticides in Europe and the United Kingdom. The company offers foliar disease and insect control, open field and greenhouses, soil pests, post-harvest shelf-life extension, and seed treatments under the Mevalone and Cedroz brands for crop protection applications. It also provides consume products, such as head-lice treatment, deodorants, odour neutralizer, and fragrances, as well as food flavourings and active ingredients; and animal health products comprising companion animal, bio-control, parasite treatments, and insect sprays. Eden Research plc was incorporated in 1995 and is headquartered in Abingdon, the United Kingdom.
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
Eden Research plc reported revenue of £4.3M in FY2024 versus £1.4M in FY2020, a compound +33.1%/yr. Reported net income was −£1.9M in FY2024.
Open the full interactive analysis →
Similar stocks
6 more Agricultural Inputs stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Corteva, Inc CTVA | $77.46 | $39.29 | -49% |
| Nutrien Ltd NTR | $68.50 | $52.75 | -23% |
| Qinghai Salt Lake Industry Co 000792 | ¥29.03 | ¥21.15 | -27% |
| CF Industries Holdings C1FI34 | R$627.77 | R$947.15 | +51% |
| Yara International ASA YAR | kr 502.80 | kr 695.65 | +38% |
| ICL Group ICL | $5.07 | $2.88 | -43% |
Explore undervalued stocks
More undervalued Basic Materials stocks →
Frequently asked questions
Is Eden Research plc (EDEN) undervalued?
What is the fair value of EDEN?
What is the quality score of EDEN?
What is the revenue of Eden Research plc (EDEN)?
What is the net profit margin of EDEN?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.